Patients with a hematological malignancy showed a trend towards a longer duration until clinical improvement and longer hospitalization time compared to patients with a solid cancer.
← all excerpts
Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany.
2
—
—
The sentences
Patients with hematological malignancies showed a nonsignificant trend for earlier occurrence of severe events compared to solid tumor patients (severe event free survival for hematological cohort = 30% vs severe event free survival for solid cohort = 61.4%, Figure 1E ), had a longer duration of hospitalization (median hematological = 21 days vs median solid cohort = 13 days), and required a longer time to achieve a clinical improvement (median hematological cohort = 18.5 days vs median solid cohort = 11.5 days). 3.7.